United Capital Financial Advisors LLC Acquires 6,401 Shares of DexCom, Inc. (NASDAQ:DXCM)

United Capital Financial Advisors LLC increased its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 56.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 17,649 shares of the medical device company's stock after buying an additional 6,401 shares during the quarter. United Capital Financial Advisors LLC's holdings in DexCom were worth $1,373,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of DXCM. Watts Gwilliam & Co. LLC acquired a new stake in shares of DexCom during the 4th quarter valued at approximately $3,334,000. Congress Asset Management Co. increased its stake in shares of DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the period. Janney Montgomery Scott LLC raised its holdings in shares of DexCom by 2,226.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock valued at $18,085,000 after buying an additional 222,548 shares during the last quarter. First Hawaiian Bank boosted its position in shares of DexCom by 556.1% during the fourth quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company's stock worth $1,801,000 after buying an additional 19,629 shares during the period. Finally, Proficio Capital Partners LLC acquired a new position in DexCom during the 4th quarter worth $5,812,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Up 5.1 %

DexCom stock traded up $3.43 during mid-day trading on Thursday, hitting $70.29. The company's stock had a trading volume of 1,769,180 shares, compared to its average volume of 4,230,065. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $139.24. The company has a market cap of $27.56 billion, a PE ratio of 49.16, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm's 50 day moving average is $73.83 and its 200 day moving average is $76.60.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on DXCM shares. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and increased their price target for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Morgan Stanley raised their target price on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Finally, Cfra Research upgraded shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $99.00.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 2,634 shares of the company's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 105,009 shares of company stock worth $8,044,178. Corporate insiders own 0.32% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.